divislab glp-1 novo nordisk relation promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk grows GLP-1 market

NCOA4, nuclear receptor coactivator 4

Ask your prescribing clinician and dispensing pharmacy to identify the precise active ingredient in your prescription and confirm it doesn't use semaglutide sodium or semaglutide acetate - the FDA states these salt forms differ from the active ingredient used in approved products and that it isn't aware of a lawful basis for their use in compounding

Donny Ramadhan (The University of Osaka, Japan) for their valuable comments and constructive suggestions on this work

As of 28 October 2024, the UK Government's med watch database (MHRA) received over 7,000 reports of gastrointestinal side effects linked to GLP-1RAs, with some resulting in hospitalization

Doctors are frustrated that theyve made health disparities worse

Rushworth, G.F